Hydrogen sulfide release via the ACE inhibitor Zofenopril prevents intimal hyperplasia in human vein segments and in a mouse model of carotid artery stenosis

Diane MACABREY^{a,b,§}, Céline DESLARZES-DUBUIS^{a,b,§}, Alban LONGCHAMP^{a,b}, Martine LAMBELET^{a,b}, Charles K. OZAKI^c, Jean-Marc CORPATAUX^{a,b}, Florent ALLAGNAT^{a,b,#} and Sébastien DÉGLISE^{a,b,#}

^aDepartment of Vascular Surgery, Lausanne University Hospital, Switzerland

^bDepartment of Biomedical Sciences, University of Lausanne, Switzerland

^cDepartment of Surgery and the Heart and Vascular Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

[§] *These authors have equally contributed as first authors*

[#] *These authors have equally contributed as senior authors*

Running title: Zofenopril inhibits intimal hyperplasia

Word count: 3769

Number of Figures: 6

Original article/basic research

Corresponding Author:

Florent Allagnat

CHUV-Service de chirurgie vasculaire

Département des Sciences Biomédicales

Bugnon 7A, 1005 Lausanne, Suisse

+41216925582

Florent.allagnat@chuv.ch

Graphical Abstract

32

33 What this paper adds

34 The current strategies to reduce intimal hyperplasia (IH) principally rely on local drug delivery, in
35 endovascular approach. The oral angiotensin converting enzyme inhibitor (ACEi) Zofenopril has
36 additional effects compared to other non-sulphyhydrated ACEi to prevent intimal hyperplasia and
37 restenosis. Given the number of patients treated with ACEi worldwide, these findings call for further
38 prospective clinical trials to test the benefits of sulphyhydrated ACEi over classic ACEi for the
39 prevention of restenosis in hypertensive patients.

40

41 **Abstract**

42 **Objectives**

43 Hypertension is a major risk factor for intimal hyperplasia (IH) and restenosis following
44 vascular and endovascular interventions. Pre-clinical studies suggest that hydrogen sulfide (H₂S), an
45 endogenous gasotransmitter, limits restenosis. While there is no clinically available pure H₂S
46 releasing compound, the sulfhydryl-containing angiotensin-converting enzyme inhibitor Zofenopril is
47 a source of H₂S. Here, we hypothesized that Zofenopril, due to H₂S release, would be superior to
48 other non-sulphydryl containing angiotensin converting enzyme inhibitor (ACEi), in reducing intimal
49 hyperplasia.

50 **Materials**

51 Spontaneously hypertensive male Cx40 deleted mice (Cx40^{-/-}) or WT littermates were
52 randomly treated with Enalapril 20 mg (Mepha Pharma) or Zofenopril 30 mg (Mylan SA). Discarded
53 human vein segments and primary human smooth muscle cells (SMC) were treated with the active
54 compound Enalaprilat or Zofenoprilat.

55 **Methods**

56 IH was evaluated in mice 28 days after focal carotid artery stenosis surgery and in human
57 vein segments cultured for 7 days *ex vivo*. Human primary smooth muscle cell (SMC) proliferation
58 and migration were studied *in vitro*.

59 **Results**

60 Compared to control animals (intima/media thickness=2.3±0.33), Enalapril reduced IH in Cx40^{-/-}
61 hypertensive mice by 30% (1.7±0.35; p=0.037), while Zofenopril abrogated IH (0.4±0.16; p<.0015 vs.
62 Ctrl and p>0.99 vs. sham-operated Cx40^{-/-} mice). In WT normotensive mice, enalapril had no effect
63 (0.9665±0.2 in control vs 1.140±0.27; p>.99), while Zofenopril also abrogated IH (0.1623±0.07,
64 p<.008 vs. Ctrl and p>0.99 vs. sham-operated WT mice). Zofenoprilat, but not Enalaprilat, also
65 prevented intimal hyperplasia in human veins segments *ex vivo*. The effect of Zofenopril on carotid
66 and SMC correlated with reduced SMC proliferation and migration. Zofenoprilat inhibited the MAPK
67 and mTOR pathways in SMC and human vein segments.

68 **Conclusion**

69 Zofenopril provides extra beneficial effects compared to non-sulphydryl ACEi to reduce SMC
70 proliferation and restenosis, even in normotensive animals. These findings may hold broad clinical
71 implications for patients suffering from vascular occlusive diseases and hypertension.

72 **Keywords:** Intimal hyperplasia; smooth muscle cells; proliferation; hydrogen sulfide; zofenopril;
73 hypertension; ACE inhibitor; restenosis

74

75

76

77 **Abbreviations**

78 ACE: angiotensin converting enzyme

79 CAS: carotid artery stenosis

80 Cx40: connexin 40

81 H₂S: hydrogen sulfide

82 IH: intimal hyperplasia

83 PCNA: proliferating cell nuclear antigen

84 SBP: systolic blood pressure

85 VSMC: vascular smooth muscle cells

86 VGEL: Van Gieson elastic lamina

87

88 INTRODUCTION

89 Intimal hyperplasia (IH) remains the major cause of restenosis following vascular surgery,
90 leading to potential limb loss and death. IH develops in response to vessel injury, leading to
91 inflammation, vascular smooth muscle cells (SMCs) dedifferentiation, migration, proliferation and
92 secretion of extra-cellular matrix. Despite decades of research, there is no effective medication to
93 prevent restenosis¹. The only validated therapy against intimal hyperplasia is the local drug-delivery
94 strategy, especially used in endovascular approach. However, this strategy seems to be limited in
95 time², speaking for other complementary oral treatment, targeting either steps involved in IH, such
96 as SMC proliferation, or risk factors for restenosis such as hypertension.

97 Hydrogen Sulfide (H₂S) is an endogenously produced gasotransmitter³. Pre-clinical studies
98 have shown that H₂S has cardiovascular protective properties⁴, including reduction of IH⁵⁻⁷, possibly
99 via decreased VSMC proliferation^{6,8}. However, there is currently no clinically approved H₂S donor⁹.

100 Hypertension is a known risk factor for restenosis and bypass failure¹⁰. Current guidelines
101 recommend angiotensin converting enzyme inhibitors (ACEi) as first line therapy for the treatment
102 of essential hypertension¹¹. Although various ACEi reduce restenosis in rodent models¹², prospective
103 clinical trials failed to prove efficacy of the ACEi Quinapril¹³ or Cilazapril^{14,15} for the prevention of
104 restenosis at 6 months following coronary angioplasty. Several *in vitro* studies suggest that the ACEi
105 Zofenopril, due to a sulfhydryl moiety in its structure, releases H₂S¹⁶⁻¹⁸. The therapeutic potential of
106 sulfhydryl ACEi Zofenopril has never been tested in the context of restenosis.

107 The purpose of this study was to test whether Zofenopril, due to its H₂S-releasing properties,
108 is superior to non-sulfhydryl ACEi in limiting IH in a surgical mouse model of IH *in vivo*, and in an *ex*
109 *vivo* model of IH in human vein culture. Zofenopril was systematically compared to the non-
110 sulfhydrated ACEi Enalapril.

111

112 MATERIALS and METHODS

Materials

113 Drugs and reagents are described in supplemental table S1. Datasets are available at
114 <https://doi.org/10.5281/zenodo.5017874>

Experimental group design

115 All experiments were performed using 8 to 10 weeks old male Cx40-deleted mice (Cx40^{-/-})¹⁹
116 and wild-type littermates (WT) mice on a C57BL/6J genetic background. Mice randomly assigned to
117 the experimental groups were treated with the various ACEi at 10mg/Kg/day via the water bottle.

Blood pressure experiments

118 WT (n=22) or Cx40^{-/-} (n=18) mice were randomly divided into 3 groups: control, Enalapril and
119 Zofenopril. Basal systolic blood pressure was measured for 4 days then treatments were initiated
120 and SBP was measured for 10 more days. WT groups were done in parallel (n=22) with Cx40^{-/-} (n=6)
121 untreated mice. Cx40^{-/-} groups (n=18) were done in parallel with WT untreated mice (n=6).

Wild type mice (n=12) were randomly divided into 3 groups: control (n=4), Quinapril (n=4) and Lisinopril (n=4). Basal systolic blood pressure was measured for 4 days then treatments were initiated and SBP was measured for 10 more days.

Systolic blood pressure (SBP) was monitored daily by non-invasive plethysmography tail cuff method (BP-2000, Visitech Systems Inc.) on conscious mice²⁰.

Mouse carotid artery stenosis model

WT mice (n=26) were divided into 3 groups: ctrl (n=9), Enalapril (n=9) and zofenopril (n=8). Cx40^{-/-} mice (n=24) were divided into 3 groups: ctrl (n=11), Enalapril (n=6) and zofenopril (n=7). Seven days post-treatment, intimal hyperplasia was induced via a carotid stenosis.

The carotid artery stenosis (CAS) was performed as previously published²¹. For surgery, mice were anesthetized with Ketamine 80mg/kg and Xylazine 15 mg/kg. The left carotid artery was located and separated from the jugular vein and vagus nerve. Then, a 7.0 PERMA silk (Johnson & Johnson AG, Ethicon, Switzerland) thread was looped under the artery and tightened around the carotid in presence of a 35-gauge needle. The needle was removed, thereby restoring blood flow, albeit leaving a significant stenosis²¹. Buprenorphine 0.05 mg/kg was provided as post-operative analgesic every 12h for 48 hours. Treatment with the ACEi of choice was continued for 28 days post-surgery until organ collection. In another set of surgeries, WT mice (n=17) were randomly divided into 3 groups: control (n=6), quinapril (n=6) and Lisinopril (n=5). Seven days post-treatment, intimal hyperplasia was induced via a carotid stenosis.

All mice were euthanized 28 days post-surgery under general anesthesia by cervical dislocation and exsanguination, perfused with PBS followed by buffered formalin 4% through the left ventricle, and carotids were taken for IH measurements.

All animal experimentation conformed to the *National Research Council: Guide for the Care and Use of Laboratory Animals*²². All animal care, surgery, and euthanasia procedures were approved by the Centre Hospitalier Universitaire Vaudois (CHUV) and the Cantonal Veterinary Office (Service de la Consommation et des Affaires Vétérinaires SCAV-EXPANIM, authorization number 3258).

Ex vivo static human vein culture and SMC culture

Human veins segments were discarded tissue obtained during lower limb bypass surgery. Each native vein was cut into 7mm segments randomly distributed between conditions (D0, D7-Ctrl, D7-enalaprilat or D7-zofenoprilat). One segment (D0) was immediately flash frozen in liquid nitrogen or OCT compound and the other were maintained in culture for 7 days in RPMI-1640 Glutamax supplemented with 10 % FBS and 1% antibiotic solution (10,000 U/mL penicillin G, 10,000 U/mL streptomycin sulphate) at 37°C and 5% CO₂, as previously described⁶. The cell culture medium was changed every 48 h with fresh ACEi. 6 different veins/patients were included in this study.

Human vascular smooth muscle cells (VSMC) were prepared and cultured from human saphenous vein segments as previously described^{6,19}. The study protocols for organ collection and use were reviewed and approved by the Centre Hospitalier Universitaire Vaudois (CHUV) and the Cantonal Human Research Ethics Committee (<http://www.cer-vd.ch/>, no IRB number, Protocol Number 170/02), and are in accordance with the principles outlined in the Declaration of Helsinki of

1975, as revised in 1983 for the use of human tissues. 6 different veins/patients were used in this study to generate VSMC.

Histomorphometry

Left ligated carotids were isolated and paraffin-embedded. Six 6 μ m cross sections were collected every 100 μ m and up to 2 mm from the ligature, and stained with Van Gieson Elastic Lamina (VGEL) staining. For intimal and medial thickness, 72 (12 measurements/cross section on six cross sections) measurements were performed¹⁹. To account for the gradient of IH in relation to the distance from the ligature, the intima thickness was plotted against the distance to calculate the area under the curve of intima thickness. Mean intima and media thickness over the 2mm distance were calculated as well.

For human vein segments, after 7 days in culture, or immediately upon vein isolation (D0), segments were fixed in buffered formalin, embedded in paraffin and cut into 6 μ m sections, and stained with VGEL as previously described⁶. For intimal and medial thickness, 96 (4 measurements/photos and 4 photos per cross section on six cross sections) measurements were performed¹⁹. Two independent researchers blinded to the conditions did the morphometric measurements using the Olympus Stream Start 2.3 software (Olympus, Switzerland)^{6, 19}.

Immunohistochemistry

PCNA (proliferating cell nuclear antigen) immunohistochemistry was performed on paraffin sections as previously described⁶ after antigen retrieval using TRIS-EDTA buffer, pH 9, 17 min in a microwave at 500 watts. Immunostaining was performed using the EnVision +/HRP, DAB+ system according to manufacturer's instructions (Dako, Switzerland), and counterstained with hematoxylin. One slide per series was assessed and 3 images per section were taken at 200x magnification. Two independent observers unaware of the conditions manually counted the PCNA and hematoxylin positive nuclei.

Live-cell hydrogen sulfide measurement

Free sulfide was measured in cells using 5 μ M SF₇-AM fluorescent probe as previously described⁶. Fluorescence intensity (λ_{ex} = 495 nm; λ_{em} = 520 nm) was measured continuously in a Synergy Mx fluorescent plate reader (Biotek AG, Switzerland) at 37 °C before and after addition of various compounds, as indicated.

Persulfidation protocol

Persulfidation protocol was performed using a dimedone-based probe as recently described²³. Flash-frozen liver was grinded into powder and 20mg of powder was homogenized in 300 μ l of HEN buffer (100mM HEPES, 1mM EDTA, 100 μ M neocuproin, 1 vol. % NP-40, 1 wt. % SDS, proteases inhibitors) supplemented with 5mM 4-Chloro-7-nitrobenzofurazan. Proteins were extracted by methanol/chloroform/water protein precipitation and the pellet was resuspended in 200 μ l of 50mM HEPES-2 wt. % SDS. Protein content was measured using Pierce BCA protein assay kit, and 75 μ g of proteins were incubated with 25 μ M final Daz-2-biotin for 1h in the dark at 37°C. Daz-2-biotin was prepared with 1mM Daz-2, 1mM alkynyl biotin, 2mM copper(II)-TBTA, 4mM ascorbic acid with overnight incubation at RT, followed by quenching with 20mM EDTA. Proteins were then extracted by Methanol/Chloroform/Water protein precipitation and the pellets resuspended in

150µl SDS lysis buffer. Protein concentration was measured using the DC protein assay, 10 µg were loaded on SDS-PAGE and the Biotin signal was measured by WB analyses using a streptavidin-HRPO antibody. Protein abundance was normalized to total protein staining using Pierce™ Reversible Protein Stain Kit for PVDF Membranes.

BrdU staining (VSMC proliferation)

VSMC were grown at 80% confluence on glass coverslips in a 24-well plate and starved overnight in serum-free medium. Then, VSMC were either treated or not (ctrl) with the ACEi of choice for 24h in full medium (RPMI 10% FBS) in presence of 10µM BrdU. All conditions were tested in parallel. All cells were fixed in ice-cold methanol 100% after 24h of incubation and immunostained for BrdU. Images were acquired using a Nikon Eclipse 90i microscope. BrdU-positive nuclei and total DAPI-positive nuclei were automatically detected using the ImageJ software⁶.

Wound healing assay (VSMC migration)

VSMC were grown at confluence in a 12-well plate and starved overnight in serum-free medium. Then, a scratch wound was created using a sterile p200 pipette tip and medium was changed to full medium (RPMI 10% FBS). Repopulation of the wounded areas was recorded by phase-contrast microscopy over 24 hours in a Nikon Ti2-E live cell microscope. The area of the denuded area was measured at t=0h and t=10h after the wound using the ImageJ software by two independent observers blind to the conditions.

Western blotting

Human vein segments were washed twice in ice-cold PBS, flash-frozen in liquid nitrogen, grinded to power and resuspended in SDS lysis buffer (62.5 mM TRIS pH6.8, 5% SDS, 10 mM EDTA).

Vascular smooth muscle cells were kept in serum free media overnight. The next morning, complete media was added with the ACEinhibitors. Five hours post-treatment, cells were washed once with ice-cold PBS and directly lysed with Laemmli buffer. Lysates were resolved by SDS-PAGE and transferred to a PVDF membrane (Immobilon-P, Millipore AG, Switzerland). Immunoblot analyses were performed as previously described⁶ using the antibodies described in the **Supplemental Table S1**. Blots were revealed by enhanced chemiluminescence (Immobilon, Millipore) using the ChemiDoc™ XRS+ System and analysed using the Image Lab (BETA2) software, version 3.0.01 (Bio-Rad Laboratories, Switzerland).

Statistical analyses

All experiments were quantitatively analysed using GraphPad Prism® 8, and results are shown as mean ± SEM. Statistical test details are indicated in the Figure legends.

RESULTS

Zofenopril and enalapril similarly lower systolic blood pressure of hypertensive mice

Spontaneously hypertensive Cx40 deleted mice (Cx40^{-/-}) and wild-type littermates (WT) were given either 10 mg/kg Zofenopril or 6 mg/kg Enalapril in the drinking water to achieve similar blood lowering effects on hypertensive Cx40^{-/-} mice (**Figure 1A**). Zofenopril also lowered by 6mmHg SBP in

normotensive WT mice (**Figure 1B**). The ACEi Enalapril (**Figure 1B**), Quinapril (10 mg/kg) and Lisinopril (10 mg/kg) had no effect on SBP in WT mice (**Figure S1**).

Zofenopril is superior to other ACEi in reducing IH in a mouse model of carotid artery stenosis

As expected, the hypertensive mice developed twice more IH than their normotensive littermates following the carotid artery stenosis (CAS) model²¹. Enalapril had a non-specific tendency to reduce IH in Cx40^{-/-} mice (I/M p>.99), while Zofenopril suppressed IH by 90% (I/M p=.0006; **Figure 2, table S2**). Enalapril had no effect in normotensive WT mice (I/M p>.99), whereas Zofenopril also suppressed IH in those mice (I/M p=.008; **Figure 2, table S3**). The ACEi Quinapril and Lisinopril did not affect IH in WT mice (**Figure S2, table S4**).

Zofenoprilat prevented the development of IH in human saphenous vein segments

We next tested the effect of Zofenoprilat and Enalaprilat, the active compounds derived from pro-drugs Zofenopril and Enalapril, in our model of IH in *ex vivo* static vein culture⁶. Continuous treatment with 100 μ M Zofenoprilat, but not with Enalaprilat, fully blocked the development of IH observed in veins maintained for 7 days in culture in absence of blood flow (D7), compared to initial values in freshly isolated veins (D0) (**Figure 3, table S5**).

Zofenoprilat released H₂S.

Besides its ACEi activity, Zofenopril has been proposed to work as an H₂S donor¹⁶⁻¹⁸. *In vitro* time-lapse recording of the H₂S-selective probe SF₇-AM revealed that Zofenoprilat, but not Enalaprilat, slowly released H₂S in RPMI medium, compared to the fast-releasing NaHS salt (**Figure 4A**). Similar experiments in presence of live VSMC (**Figure 4B**) confirmed that Zofenoprilat, but not Enalaprilat, increased the SF₇-AM signal.

The biological activity of H₂S is mediated by post-translational modification of reactive cysteine residues by persulfidation, which modulates protein structure and/or function^{9, 23}. We assessed protein persulfidation using a dimedone-based probe as recently described²³. Zofenopril significantly increased protein persulfidation (PSSH) in liver extracts from mice treated with Enalapril or Zofenopril for two weeks (**Figure 4C**).

Zofenopril decreased VSMC proliferation and migration

As various H₂S donors decrease VSMC proliferation in the context of IH^{6, 8}, we next tested the effect of Zofenopril on VSMC. In the CAS model, Zofenopril, but not Enalapril, lowered cell proliferation in the carotid wall as assessed by PCNA staining (**Figure 5A-B**). Zofenoprilat further inhibited the proliferation and migration of primary human VSMC *in vitro*, while Enalaprilat had no effect on proliferation (**Figure 5C-D**) and reduced migration by 20% (**Figure 5E-F**). ACEi Lisinopril and Quinaprilat did not affect VSMC proliferation (**Figure S3**).

Zofenoprilat inhibited the MAPK and mTOR pathways

The MAPK and mTOR signalling pathways contribute to VSMC proliferation in the context of IH²⁴. Western blot analyses revealed that Zofenoprilat reduced by 50% the levels of P-ERK1,2, P-p38 and P-S6RP in cultured VSMC, while Enalaprilat had no effect (**Figure 6A-F**). Moreover, P-S6RP and P-ERK1,2 levels were also decreased by Zofenoprilat in human vein segments placed in culture for 7 days (**Figure 6G-I**).

DISCUSSION

In this study, we hypothesized that Zofenopril, an ACEi with a free thiol moiety acting as an H₂S donor, would be more efficient than other ACEi to inhibit IH in the context of hypertension. Not only Zofenopril is more potent than Enalapril in reducing IH in hypertensive Cx40^{-/-} mice, it also suppresses IH in normotensive condition, where other ACEi have no effect. Furthermore, Zofenopril prevents IH in human saphenous vein segments in absence of blood flow. The effect of Zofenopril on IH correlates with reduced VSMC proliferation and migration and decreased activity of the MAPK and mTOR pathways.

Several pre-clinical studies have shown that that SBP-lowering medication such as ACEi reduce IH¹², which prompt the large-scale MERCATOR/MARCATOR^{14, 15} and PARIS clinical trials¹³. Here, we also observed that lowering SBP using the ACEi Enalapril had a non-significant tendency to protect from IH in hypertensive mice. However, Enalapril, Quinapril and Lisinopril, had no effect in normotensive WT mice. The fact that the sulhydrated ACEi Zofenopril almost abrogated IH in hypertensive and normotensive mice strongly supports that this ACEi provides additional effects independent of its ACEi activity, as previously suggested¹⁶⁻¹⁸. Of interest, the SMILE clinical trials concluded that, compared to placebo or Ramipril, Zofenopril reduces the 1-year risk of cardiovascular events after acute myocardial infarction²⁵. These benefits might be related to H₂S release by Zofenopril, as pre-clinical studies consistently show that H₂S supplementation promote recovery after acute myocardial infarction⁴.

Zofenopril has been proposed to work as a H₂S donor in several studies¹⁶⁻¹⁸. Here, we confirmed that Zofenoprilat releases detectable amounts of H₂S. H₂S modifies proteins by post-translational persulfidation (S-sulfhydration) of reactive cysteine residues, which modulate protein structure and/or function²³. Here, we further observed that Zofenopril increases overall protein persulfidation *in vivo*, suggesting that Zofenopril generates H₂S *in vivo* as well.

We and others previously demonstrated that various H₂S donors inhibit VSMC proliferation^{6, 8, 26}. Consistently, we confirmed that Zofenopril inhibits VSMC proliferation and migration *in vitro* and reduces cell proliferation in the carotid wall *in vivo*. Although the exact mechanisms of action of Zofenoprilat and H₂S remain to be elucidated, we demonstrated that Zofenoprilat inhibits the MAPK and mTOR signalling pathways, which contribute to VSMC proliferation and neointima formation²⁴. Overall, our data strongly suggest that Zofenopril acts similarly to other known H₂S donors to limit IH through inhibition of the MAPK and mTOR signalling pathways, leading to decreased VSMC proliferation and migration.

Overall, our data suggests that Zofenopril might show benefits against restenosis in patients unlike other ACEi. These findings raise the question as to whether the scientific community was not too quick to discard the whole class of ACEi as a treatment of restenosis based on the disappointing results of the MERCATOR/MARCATOR^{14, 15} and PARIS trials¹³. In the last decade, many efforts have been put on the development of local drug delivery strategy, well adapted to endovascular interventions. However, this strategy seems to bring great improvement in the mid-term but not in the long-term follow-up². Thus, a more chronic approach, sustaining the early effect on cell

proliferation and IH inhibition, should be encouraged. Such a strategy relies on oral medication, which is also better adapted to open surgery.

Nevertheless, our study carries some limitations.

Firstly, numerous oral drugs have been clinically tested over the years to limit restenosis and, in most trials, the pharmacologic treatment of restenosis failed to show positive results, despite promising results obtained in experimental models²⁷. While there is no doubt that pre-clinical models have significantly advanced our understanding of the mechanisms of restenosis formation, none of them fully mimic restenosis in human. The genetic model of renin-dependent hypertension used in that study is also rarely observed in patients, which have complex multifactorial essential hypertension. Additional studies reflecting better the patients' comorbidities (dyslipidemia, renal insufficiency, smoking, atherosclerosis, etc..) with a vein bypass model and larger animal models, or small phase II clinical trial, are required before testing the benefits of Zofenopril in a large, phase III clinical trials.

Secondly, although Zofenopril was the only ACEi providing benefits in normotensive condition, we cannot exclude that other ACEi not tested here could work as well. We further acknowledge that pharmacokinetics and pharmacodynamics differences between Zofenopril and other ACEi may contribute to the superiority of Zofenopril. Zofenopril is more lipophilic and may have better tissue penetration than Enalapril or Ramipril, which may have an impact beyond the effect of H₂S liberated by Zofenopril. However, it has been shown that vessel wall penetration of various ACEi is independent of lipophilia and that the endothelium constitutes no specific barrier for the passage of ACE inhibitors²⁸.

Finally, our working hypothesis is that Zofenopril inhibits VSMC proliferation via direct release of H₂S at the level of the media of vessel. However, we could not ascertain that H₂S is released at the level of the VSMC. H₂S⁹ and Zofenopril^{17, 18} have been shown to promote endothelial cell function, including proliferation and migration. Thus, we cannot exclude that Zofenopril limits IH via a positive effect on endothelial cells. Further studies are required to carefully assess the impact of Zofenopril on the endothelium and quantify H₂S in vascular tissue.

Conclusion

Under the conditions of these experiments, Zofenopril is superior to Enalapril in reducing IH and provides beneficial effect against IH in mice and in a model of IH in human vein segments *ex vivo*. Our data strongly support that Zofenopril limits the development of IH via H₂S release, independently of its ACEi activity. The effects of Zofenopril correlate with reduced MAPK and mTOR pathways activities, leading to decreased VSMC proliferation and migration.

Given the number of patients treated with ACEi worldwide, these findings may have broad implications for the treatment of patients suffering from peripheral atherosclerotic disease undergoing revascularization, and beyond. Our results warrant further research to evaluate the benefits of Zofenopril in limiting restenosis and eventually prospective clinical trials to test the superiority of sulfhydrylated ACEi on restenosis over other ACEi.

Acknowledgements

We thank Prof. Jacques-Antoine Haefliger for giving us the Cx40^{-/-} mice. We thank the mouse pathology facility for their services in histology (<https://www.unil.ch/mpf>).

Sources of Funding

This work was supported by the following: The Swiss National Science Foundation (grant FN-310030_176158 to FA and SD, to FA, SD and PZ00P3-185927 to AL) and the Union des Sociétés Suisses des Maladies Vasculaires (to SD), and the Novartis Foundation (to FA). The funding sources had no involvement in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Disclosures

None

350 REFERENCES

351

1. Davies MG, Hagen PO. Reprinted article "Pathophysiology of vein graft failure: a review". *Eur J Vasc Endovasc Surg*. 2011;42 Suppl 1:S19-29. DOI: 10.1016/j.ejvs.2011.06.013.
2. Phillips J. Drug-eluting stents for PAD: what does (all) the data tell us? *J Cardiovasc Surg (Torino)*. 2019;60(4):433-8. DOI: 10.23736/S0021-9509.19.10965-2.
3. Islam KN, Polhemus DJ, Donnarumma E, Brewster LP, Lefer DJ. Hydrogen Sulfide Levels and Nuclear Factor-Erythroid 2-Related Factor 2 (NRF2) Activity Are Attenuated in the Setting of Critical Limb Ischemia (CLI). *J Am Heart Assoc*. 2015;4(5). DOI: 10.1161/JAHA.115.001986.
4. Zhang L, Wang Y, Li Y, Li L, Xu S, Feng X, et al. Hydrogen Sulfide (H₂S)-Releasing Compounds: Therapeutic Potential in Cardiovascular Diseases. *Front Pharmacol*. 2018;9:1066. DOI: 10.3389/fphar.2018.01066.
5. Ma B, Liang G, Zhang F, Chen Y, Zhang H. Effect of hydrogen sulfide on restenosis of peripheral arteries after angioplasty. *Mol Med Rep*. 2012;5(6):1497-502. DOI: 10.3892/mmr.2012.853.
6. Longchamp A, Kaur K, Macabrey D, Dubuis C, Corpataux JM, Deglise S, et al. Hydrogen sulfide-releasing peptide hydrogel limits the development of intimal hyperplasia in human vein segments. *Acta Biomater*. 2019. DOI: 10.1016/j.actbio.2019.07.042.
7. Yang G, Li H, Tang G, Wu L, Zhao K, Cao Q, et al. Increased neointimal formation in cystathionine gamma-lyase deficient mice: role of hydrogen sulfide in alpha5beta1-integrin and matrix metalloproteinase-2 expression in smooth muscle cells. *J Mol Cell Cardiol*. 2012;52(3):677-88. DOI: 10.1016/j.yjmcc.2011.12.004.
8. Yang G, Wu L, Bryan S, Khaper N, Mani S, Wang R. Cystathionine gamma-lyase deficiency and overproliferation of smooth muscle cells. *Cardiovasc Res*. 2010;86(3):487-95. DOI: 10.1093/cvr/cvp420.
9. Li Z, Polhemus DJ, Lefer DJ. Evolution of Hydrogen Sulfide Therapeutics to Treat Cardiovascular Disease. *Circ Res*. 2018;123(5):590-600. DOI: 10.1161/CIRCRESAHA.118.311134.
10. Venermo M, Sprynger M, Desormais I, Bjorck M, Brodmann M, Cohnert T, et al. Editor's Choice - Follow-up of Patients After Revascularisation for Peripheral Arterial Diseases: A Consensus Document From the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases and the European Society for Vascular Surgery. *Eur J Vasc Endovasc Surg*. 2019;58(5):641-53. DOI: 10.1016/j.ejvs.2019.06.017.
11. Flu HC, Tamsma JT, Lindeman JH, Hamming JF, Lardenoye JH. A systematic review of implementation of established recommended secondary prevention measures in patients with PAOD. *Eur J Vasc Endovasc Surg*. 2010;39(1):70-86. DOI: 10.1016/j.ejvs.2009.09.027.
12. Osgood MJ, Harrison DG, Sexton KW, Hocking KM, Voskresensky IV, Komalavilas P, et al. Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure? *Ann Vasc Surg*. 2012;26(8):1130-44. DOI: 10.1016/j.avsg.2011.12.001.

13. Meurice T, Bauters C, Hermant X, Codron V, VanBelle E, Mc Fadden EP, et al. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2001;357(9265):1321-4. DOI: 10.1016/S0140-6736(00)04518-9.
14. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. *Circulation*. 1992;86(1):100-10. DOI: 10.1161/01.cir.86.1.100.
15. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. *J Am Coll Cardiol*. 1995;25(2):362-9. DOI: 10.1016/0735-1097(94)00368-z.
16. Bucci M, Vellecco V, Cantalupo A, Brancalone V, Zhou Z, Evangelista S, et al. Hydrogen sulfide accounts for the peripheral vascular effects of zofenopril independently of ACE inhibition. *Cardiovasc Res*. 2014;102(1):138-47. DOI: 10.1093/cvr/cvu026.
17. Monti M, Terzuoli E, Ziche M, Morbidelli L. H₂S dependent and independent anti-inflammatory activity of zofenoprilat in cells of the vascular wall. *Pharmacol Res*. 2016;113(Pt A):426-37. DOI: 10.1016/j.phrs.2016.09.017.
18. Terzuoli E, Monti M, Vellecco V, Bucci M, Cirino G, Ziche M, et al. Characterization of zofenoprilat as an inducer of functional angiogenesis through increased H₂ S availability. *Br J Pharmacol*. 2015;172(12):2961-73. DOI: 10.1111/bph.13101.
19. Allagnat F, Haefliger JA, Lambelet M, Longchamp A, Berard X, Mazzolai L, et al. Nitric Oxide Deficit Drives Intimal Hyperplasia in Mouse Models of Hypertension. *Eur J Vasc Endovasc Surg*. 2016;51(5):733-42. DOI: 10.1016/j.ejvs.2016.01.024.
20. Le Gal L, Alonso F, Wagner C, Germain S, Nardelli Haefliger D, Meda P, et al. Restoration of connexin 40 (Cx40) in Renin-producing cells reduces the hypertension of Cx40 null mice. *Hypertension*. 2014;63(6):1198-204. DOI: 10.1161/HYPERTENSIONAHA.113.02976.
21. Tao M, Mauro CR, Yu P, Favreau JT, Nguyen B, Gaudette GR, et al. A simplified murine intimal hyperplasia model founded on a focal carotid stenosis. *Am J Pathol*. 2013;182(1):277-87. DOI: 10.1016/j.ajpath.2012.10.002.
22. National Research Council (U.S.). Committee for the Update of the Guide for the Care and Use of Laboratory Animals., Institute for Laboratory Animal Research (U.S.), National Academies Press (U.S.). Guide for the care and use of laboratory animals. 8th ed. Washington, D.C.: National Academies Press; 2011. xxv, 220 p. p.
23. Zivanovic J, Kouroussis E, Kohl JB, Adhikari B, Bursac B, Schott-Roux S, et al. Selective Persulfide Detection Reveals Evolutionarily Conserved Antiaging Effects of S-Sulfhydration. *Cell Metab*. 2019;30(6):1152-70 e13. DOI: 10.1016/j.cmet.2019.10.007.
24. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. *Physiol Rev*. 2004;84(3):767-801. DOI: 10.1152/physrev.00041.2003.

25. Borghi C, Omboni S, Novo S, Vinereanu D, Ambrosio G, Ambrosioni E. Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublished Data of the Randomized Double-Blind SMILE-4 Study. *Adv Ther.* 2018;35(5):604-18. DOI: 10.1007/s12325-018-0697-x.
26. Wang Y, Wang X, Liang X, Wu J, Dong S, Li H, et al. Inhibition of hydrogen sulfide on the proliferation of vascular smooth muscle cells involved in the modulation of calcium sensing receptor in high homocysteine. *Exp Cell Res.* 2016;347(1):184-91. DOI: 10.1016/j.yexcr.2016.08.004.
27. Seedial SM, Ghosh S, Saunders RS, Suwanabol PA, Shi X, Liu B, et al. Local drug delivery to prevent restenosis. *J Vasc Surg.* 2013;57(5):1403-14. DOI: 10.1016/j.jvs.2012.12.069.
28. Raasch W, Dendorfer A, Ball B, Dominiak P. The lipophilic properties of angiotensin I-converting enzyme inhibitors do not influence their diffusion through cultured endothelium. *Jpn J Pharmacol.* 1999;81(4):346-52. DOI: 10.1254/jjp.81.346.

352

353

354 **FIGURE LEGENDS**

Figure 1: Zofenopril and Enalapril similarly lower systolic blood pressure in hypertensive Cx40^{-/-} mice

A) Daily systolic blood pressure (SBP) values (mean±SEM) in WT (n=6) vs. Cx40^{-/-} mice treated or not (n=5) with 10mg/kg Zofenopril (n=6) and 10mg/kg Enalapril (n=6) for the indicated time. **B)** Area under the curve (AUC) of SBP from day 0 to 10. **C)** Daily systolic blood pressure values (mean±SEM) in Cx40^{-/-} (n=5) vs. WT mice treated or not (n=6) with Zofenopril (n=8) and Enalapril (n=8) for the indicated time. **D)** Area under the curve (AUC) of SBP between day 0 to 10. *p<.05; **p<.01; ***p<.001 as indicated from one-way ANOVA with Tukey's correction of multiple comparisons.

Figure 2. Zofenopril treatment reduces IH in a mouse model of carotid artery stenosis

Cx40^{-/-} (A-E) or WT mice (F-J), treated or not (Ctrl) with Zofenopril (Zof) and Enalapril (Enal), were submitted to carotid artery stenosis. **A, F**) Representative images of left carotid cross sections stained with VGEL 28 days post-surgery in Cx40^{-/-} (A) or WT (F) mice. Scale bar represents 40 μm. **B-E, G-I**) Morphometric measurements of area under the curve (AUC) of intima thickness (**B, G**) intima thickness (**C, H**), media thickness (**D, I**) and intima over media ratio (**E, J**). Data are presented as scatter plots of 9 to 12 animals per group, with mean±SEM. *p<.05; **p<.01; ***p<.001 as indicated from Kruskal-Wallis test followed by Dunn's multiple comparisons tests.

Figure 3: Ex vivo treatment with Zofenoprilat prevents the development of IH in human saphenous vein segments

Human great saphenous vein segments obtained from donors who underwent lower limb bypass surgery were put or not (D0, n=6) in static culture for 7 days in presence or not (D7, n=6) of 100 μ M of Zofenoprilat (n=6) or Enalaprilat (n=5). **A**) Representative VGEL staining. Scale bar= 50 μ m. **B-D**) Morphometric measurements of intima thickness (**B**), media thickness (**C**) and intima over media ratio (**D**). Data are presented as scatter plots of 6 different vein/patient with mean $\pm$ SEM. * p <.05; ** p <.01 as indicated from repeated measures one-way ANOVA with post-hoc t-test with Dunnet's correction of multiple comparisons.

Figure 4. Zofenoprilat release H₂S as measured by SF₇-AM fluorescent probe

A-B SF₇-AM fluorescent signal (mean ± SEM) in a cell free assay in RPMI medium (**A**), in live primary VSMC (**B**) exposed or not (Ctrl) to 100 μM NaHS, 100 μM Zofenoprilat or 100 μM Enalaprilat for the indicated time. *p<.05; **p<.01; ***p<.001 vs. respective ctrl as determined by repeated measures two-way ANOVA with post-hoc t-test with Tukey's correction for multiple comparisons. Data are representative of 3 individual experiments. **C** Global protein persulfidation (PSSH; labelled with DAz-2:Biotin as a switching agent) over total proteins in liver extracts from C57BL/6J male mice treated for two weeks with Enalapril or Zofenopril. Data are presented as scatter plots of 5 to 6 animals/group with mean±SEM with *p<.05, **p<.01, as determined by one-way ANOVA with post-hoc t-test with Tukey's correction for multiple comparisons.

Figure 5. Zofenopril treatment reduces cell proliferation in a mouse model of carotid artery stenosis

A-B) PCNA immunostaining 28 days post carotid artery stenosis in WT (Cx40^{+/+}) or Cx40^{-/-} mice treated or not (Ctrl) with Zofenopril (Zof) and Enalapril (Enal). **A)** Representative images of PCNA-positive nuclei (brown) and negative nuclei (haematoxylin-stained blue nuclei). Scale bar represents 40 μ m. **B)** Quantitative assessment of PCNA positive cells over total cells of 5 to 8 animals/group with mean $\pm$ SEM. * p <.05; ** p <.01; *** p <.001, as determined by two-way ANOVA with post-hoc t-test with Sidak's correction of multiple comparisons. **C-D)** Primary human vascular smooth muscle cells (VSMC) were exposed or not (Ctrl) to 100 μ M Zofenoprilat or Enalaprilat for 24 h in presence of BrdU. **C)** Representative images of BrdU-positive nuclei (pink) and DAPI-stained nuclei (blue). Bar scale represents 10 μ m. **D)** Proliferation was calculated as the percentage of BrdU-positive nuclei over total nuclei. Data are scatter plots of 8 independent experiments with mean $\pm$ SEM with * p <.05, ** p <.01, as determined by repeated measures one-way ANOVA with post-hoc t-test with Dunnet's correction for multiple comparisons. **E-F)** Wound healing assay with VSMC exposed or not (Ctrl) to

100 μ M Zofenoprilat or Enalaprilat. E) Representative images of VSMC in brightfield 10 hours post wound. Scale bar represents 50 μ m. F) Data are scatter plots of 7 independent experiments with mean $\pm$ SEM of wound area after 10h, expressed as a percentage of the initial wound area. **p<.01, ***p<.001, as determined by repeated measures one-way ANOVA with post-hoc t-test with Dunnet's correction for multiple comparisons.